Projected most valuable R&D projects based on net present value 2023
This statistic displays the top pharmaceutical R&D projects based on net present value, as of December 2023. According to the source, the top R&D project was Novo Nordisk's fixed-dose combination for type 2 diabetes and obesity Cagrisema, with a net present value of over 30 billion U.S. dollars at that time.